111 related articles for article (PubMed ID: 18602252)
1. Ceftazidime-resistant Klebsiella oxytoca producing an OXY-2-type variant from Switzerland.
Rodríguez-Martínez JM; Poirel L; Nordmann P; Fankhauser C; Francois P; Schrenzel J
Int J Antimicrob Agents; 2008 Sep; 32(3):278-9. PubMed ID: 18602252
[No Abstract] [Full Text] [Related]
2. Plasmid-mediated, inducible AmpC beta-lactamase (DHA-1)-producing Enterobacteriaceae at a Korean hospital: wide dissemination in Klebsiella pneumoniae and Klebsiella oxytoca and emergence in Proteus mirabilis.
Yong D; Lim Y; Song W; Choi YS; Park DY; Lee H; Yum JH; Lee K; Kim JM; Chong Y
Diagn Microbiol Infect Dis; 2005 Sep; 53(1):65-70. PubMed ID: 15936167
[TBL] [Abstract][Full Text] [Related]
3. Overproduction of K1 enzyme in Klebsiella oxytoca clinical isolates against ceftazidime, cefepime and ceftobiprole.
Corvec S; Cremet L; Lepelletier D; Reynaud A; Drugeon H
J Chemother; 2009 Jun; 21(3):365-6. PubMed ID: 19567362
[No Abstract] [Full Text] [Related]
4. False-positive extended-spectrum beta-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 beta-lactamase.
Potz NA; Colman M; Warner M; Reynolds R; Livermore DM
J Antimicrob Chemother; 2004 Mar; 53(3):545-7. PubMed ID: 14963067
[No Abstract] [Full Text] [Related]
5. Emergence of Serratia liquefaciens and Klebsiella oxytoca with metallo-beta-lactamase-encoding IncW plasmids: further spread of the blaVIM-1-carrying integron In-e541.
Miriagou V; Douzinas EE; Papagiannitsis CC; Piperaki E; Legakis NJ; Tzouvelekis LS
Int J Antimicrob Agents; 2008 Dec; 32(6):540-1. PubMed ID: 18786812
[No Abstract] [Full Text] [Related]
6. Analysis of plasmid-mediated multidrug resistance in Escherichia coli and Klebsiella oxytoca isolates from clinical specimens in Japan.
Ode T; Saito R; Kumita W; Sato K; Okugawa S; Moriya K; Koike K; Okamura N
Int J Antimicrob Agents; 2009 Oct; 34(4):347-50. PubMed ID: 19560903
[TBL] [Abstract][Full Text] [Related]
7. OXY-2-15, a novel variant showing increased ceftazidime hydrolytic activity.
Nijhuis RH; Oueslati S; Zhou K; Bosboom RW; Rossen JW; Naas T
J Antimicrob Chemother; 2015 May; 70(5):1429-33. PubMed ID: 25630648
[TBL] [Abstract][Full Text] [Related]
8. Outbreak of OXY-2-Producing Klebsiella oxytoca in a renal transplant unit.
Zárate MS; Gales AC; Picão RC; Pujol GS; Lanza A; Smayevsky J
J Clin Microbiol; 2008 Jun; 46(6):2099-101. PubMed ID: 18417660
[TBL] [Abstract][Full Text] [Related]
9. In vivo selection of a chromosomally encoded beta-lactamase variant conferring ceftazidime resistance in Klebsiella oxytoca.
Mammeri H; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2003 Dec; 47(12):3739-42. PubMed ID: 14638475
[TBL] [Abstract][Full Text] [Related]
10. Phylogenetic lineages, clones and β-lactamases in an international collection of Klebsiella oxytoca isolates non-susceptible to expanded-spectrum cephalosporins.
Izdebski R; Fiett J; Urbanowicz P; Baraniak A; Derde LP; Bonten MJ; Carmeli Y; Goossens H; Hryniewicz W; Brun-Buisson C; Brisse S; Gniadkowski M; ;
J Antimicrob Chemother; 2015 Dec; 70(12):3230-7. PubMed ID: 26318191
[TBL] [Abstract][Full Text] [Related]
11. First report of a novel extended-spectrum beta-lactamase KOXY-2 producing Klebsiella oxytoca that hydrolyses cefotaxime and ceftazidime.
Younes A; Hamouda A; Amyes SG
J Chemother; 2011 Jun; 23(3):127-30. PubMed ID: 21742579
[TBL] [Abstract][Full Text] [Related]
12. First isolation of bla(VIM-2) in Klebsiella oxytoca clinical isolates from Portugal.
Conceição T; Brízio A; Duarte A; Barros R
Antimicrob Agents Chemother; 2005 Jan; 49(1):476. PubMed ID: 15616343
[No Abstract] [Full Text] [Related]
13. Six groups of the OXY beta-Lactamase evolved over millions of years in Klebsiella oxytoca.
Fevre C; Jbel M; Passet V; Weill FX; Grimont PA; Brisse S
Antimicrob Agents Chemother; 2005 Aug; 49(8):3453-62. PubMed ID: 16048960
[TBL] [Abstract][Full Text] [Related]
14. [ESBL-positive and ESBL-negative Klebsiella pneumoniae and Klebsiella oxytoca strains--occurrence in clinical specimens and susceptibility to selected antibiotics].
Sekowska A; Wróblewska J; Gospodarek E
Med Dosw Mikrobiol; 2008; 60(1):39-44. PubMed ID: 18634342
[TBL] [Abstract][Full Text] [Related]
15. SME-2-producing Serratia marcescens isolate from Switzerland.
Poirel L; Wenger A; Bille J; Bernabeu S; Naas T; Nordmann P
Antimicrob Agents Chemother; 2007 Jun; 51(6):2282-3. PubMed ID: 17420208
[No Abstract] [Full Text] [Related]
16. Providencia stuartii with VIM-1 metallo-beta-lactamase.
Miriagou V; Tzouvelekis LS; Flevari K; Tsakiri M; Douzinas EE
J Antimicrob Chemother; 2007 Jul; 60(1):183-4. PubMed ID: 17517828
[No Abstract] [Full Text] [Related]
17. SHV-12 extended spectrum beta-lactamase associated with high-level ceftazidime resistance in Enterobacter cloacae isolated from Thailand.
Tansawai U; Boonkerd N; Polwichai P; Dejsirilert S; Niumsup PR
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):148-54. PubMed ID: 19323047
[TBL] [Abstract][Full Text] [Related]
18. Isolation of multidrug-resistant Klebsiella oxytoca carrying blaIMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain.
Conejo MC; Domínguez MC; López-Cerero L; Serrano L; Rodríguez-Baño J; Pascual A
J Antimicrob Chemother; 2010 May; 65(5):1071-3. PubMed ID: 20215129
[No Abstract] [Full Text] [Related]
19. Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate.
Pérez-Llarena FJ; Fernández A; Zamorano L; Kerff F; Beceiro A; Aracil B; Cercenado E; Miro E; Oliver A; Oteo J; Navarro F; Bou G
Antimicrob Agents Chemother; 2012 Aug; 56(8):4540-3. PubMed ID: 22668859
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of tigecycline against enterobacteria producing two or more extended-spectrum beta-lactamases.
Vázquez MF; Romero ED; García MI; Rodríguez JA; Bellido JL
Int J Antimicrob Agents; 2008 Dec; 32(6):541-3. PubMed ID: 18789848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
